TP53 and B-cell chronic lymphocytic leukemia: Overall, Phase III data now support the use of ibrutinib-based regimens over CIT for the majority of patients with CLL, with particular benefit for elderly patients not previously eligible for the most effective CIT regimens and patients whose disease bears TP53 abnormalities in whom durable responses now commonly seen with ibrutinib were previously rare.